Industry News

Ionis Pharmaceuticals, Inc. announced today that it will host a live webcast on Tuesday, August 9 at 11:30 a.m. Eastern Time to discuss its second quarter 2016 financial results, and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address."/>
Webcast Alert: Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Conference Call
Tokai Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it plans to discontinue the ARMOR3-SV clinical trial, the company’ s pivotal Phase 3 study comparing galeterone to enzalutamide..."/>
Tokai Pharmaceuticals Announces Clinical Update
Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its operational highlights and financial results for the three and six months ending June 30, 2016, on Wednesday, August 3, 2016, and to host a conference call the same day at 4:30 p.m. EDT. Participants are asked to dial in 15 minutes before the start of the call..."/>
Synthetic Biologics to Report Second Quarter 2016 Operational Highlights and Financial Results on August 3, 2016
Waters Corporation reported second quarter 2016 sales of $537 million, an 8% increase versus sales of $495 million in the second quarter of 2015."/>
Waters Reports Second Quarter 2016 Financial Results
CytoDyn Inc., a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, announces the enrollment of the first patient under a recently modified protocol in the Company’ s Phase 3 combination study with PRO 14 O. The modified protocol has been cleared by the U.S. Food and Drug Administration and features a 50% reduction in enrollment to 150 subjects and relaxed..."/>
First Patient Enrolled Under Newly Modified Protocol in CytoDyn’s Phase 3 PRO 140 Combination Study in HIV
Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, today unveiled Signature Solutions™, a comprehensive suite of clinical services and technologies designed to assist hospitals and medical practices to seamlessly transition to value-based healthcare models by maintaining excellent patient outcomes, while maximizing procedural and cost efficiencies across the entire episode of care."/>
Zimmer Biomet Unveils Signature Solutions™
ICON Reports Second Quarter 2016 Results
Centene Corporation today announced its financial results for the second quarter ended June 30, 2016. The following discussions, with the exception of cash flow information, are in the context of continuing operations. For the second quarter of 2016, we reported diluted earnings per share of $0.98 and adjusted diluted earnings per share of $1.29 when excluding Health Net acquisition related expenses and amortization of acquired intangible..."/>
Centene Corporation Reports 2016 Second Quarter Results
Exact Sciences Corp. today announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161- percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015."/>
Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
Aetna and Humana, Georgia officials are delaying a state-level look at the issue. Aetna Inc. wants to purchase Humana Inc. in a $33 billion deal."/>
BRIEF: Georgia officials postpone Aetna-Humana merger hearing [The Albany Herald, Ga.]
Liberty Property Trust is under agreement to sell much of its holdings in the Great Valley Corporate Center, the pioneering Chester County business park that transformed Malvern and made the developer into a major regional office landlord. The company is selling 26 Great Valley properties, accounting for over a million square feet of office and light-industrial space, to Horsham-based Workspace Property Trust, Liberty announced Monday. The properties are part of a..."/>
Liberty Property Trust to sell most Great Valley Corporate Center holdings in milestone for company [The Philadelphia Inquirer]
Biocon Ltd's shares have gained 65% since the start of this fiscal year. The stock declined a bit in early July but improved after its results last week, and is up by 17% since 21 July. While it posted a good set of numbers, that alone did not cause the recent bump."/>
Biocon: hope in the pipeline [Mint, New Delhi]
Aetna Inc. is pushing back against the Obama administration's opposition to its proposed $37 billion purchase of Humana Inc.. CEO Mark Bertolini took to Aetna's website to address the U.S. Justice Department's criticism of the deal and a $54 billion proposal by Anthem Inc. to buy Cigna Corp. U.S. officials characterized the transactions as threats to competition, consumer choice and health care quality."/>
Aetna CEO Pushes Back Against Feds' Opposition To Humana Deal [The Hartford Courant]
Express Scripts Holding Co., the nation's largest pharmacy benefit manager, reported prescriptions fell slightly during the second quarter along with revenue. Total adjusted claims declined to 315 million for the quarter ended June 30, compared with 321 million during the year-earlier period. Revenue dipped to $25.2 billion compared with $25.4 billion during the year-earlier period."/>
BRIEF: Express Scripts reports slight dip in prescriptions during 2Q, narrows guidance [St. Louis Post-Dispatch]
FibroGen, Inc., today announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat for treatment of anemia in chronic kidney disease, which triggered a $10 million milestone payment from Astellas to FibroGen. The initiation of Phase 3 studies in Japan follows the positive results from two Phase 2 studies in Japan of roxadustat in CKD patients on dialysis and in CKD patients not on dialysis.."/>
Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
Luye Pharma Group Ltd. announces its agreement to acquire the TDS business from Acino, through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for EUR245, 000,000. The Target Group is a Europe based global leader in advanced transdermal drug delivery systems and it is one of the largest independent TDS manufacturers in Europe. The TDS business includes the business of developing, producing and distributing..."/>
Luye Pharma Takes a Milestone Step Forward; Proposed Acquisition of Acino's TDS Business

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology834 Articles
Financials801 Articles
Consumer Discretionary689 Articles
Industrials522 Articles
Health Care519 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.